| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| BAFFR&CD3 BsAb - 01 | PCC | Bispecific | Humanized Mouse,Nanobody | Hematological Malignancy,AutoImmunity | Blood tumor,Autoimmune disease |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Waldenstrom Macroglobulinemia | Details | |
| Anti-BAFFR CAR T therapy(The General Hospital Of Tianjin Medical University) | BAFFR CART | Phase 2 Clinical | The General Hospital Of Tianjin Medical University | Myasthenia Gravis; Myositis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |
| ESG-206 | ESG-206 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome | Details |
| dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University) | Phase 1 Clinical | Shanghai Yake Biotechnology Co Ltd | Autoimmune Diseases; Dermatomyositis; Lupus Erythematosus, Systemic; Nephritis; Neuromyelitis Optica; Scleroderma, Systemic | Details | |
| SSS-68 | SSS68; SSS-68 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Glomerulonephritis, IGA | Details |
| BAFF-R CAR-T cells therapy (Topcel-KH Pharmaceutical) | Phase 1 Clinical | Jiangsu Topcel-KH Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details | |
| BAFFR CAR-T cell therapy (Bio-gene Technology) | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| LY-4152199 | LY-4152199; LY4152199 | Phase 1 Clinical | Eli Lilly And Company | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells therapy(Mayo Clinic) | MC10029; MC-10029 | Phase 1 Clinical | Mayo Clinic | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell | Details |
| CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Autoimmune Diseases; Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| KD-6005 | KD-6005; KD6005 | Phase 1 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd, Shanghai Kanda Bio-Technology Co Ltd | Arthritis, Rheumatoid | Details |
| Aritinercept | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
| JH-013 | JH-013 | Phase 1 Clinical | Biotech Pharmaceuticals Co Ltd | Arthritis, Rheumatoid; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Sjogren's Syndrome | Details |
| BAFFR-CAR T cell therapy (PeproMene Bio) | PMB-101; PMB-CT01 | Phase 1 Clinical | City Of Hope National Medical Center, PeproMene Bio Inc | Leukemia, Biphenotypic, Acute; Lymphoma, B-Cell; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |